XCath
About
About XCath
XCath is developing the Iris endovascular robotic system and ElectroSteer deflectable guidewire for navigating complex blood vessels. Iris places a robotic cassette beside the patient and gives the physician console control of compatible guidewires, catheters and treatment devices with submillimetre positioning, supporting both local operation and remote intervention while separating the operator from fluoroscopy radiation.
ElectroSteer uses a microfabricated Nitinol and stainless-steel shaft with an electrically actuated, radiopaque distal tip that deflects in two directions. It can connect to Iris or a battery-powered handheld controller to reach difficult neurovascular anatomy. The platform has completed first-in-human brain-aneurysm procedures and a remote robotic stroke intervention, but Iris remains under development and is not commercially available.
Products
- Iris Endovascular Robotic System
Iris Endovascular Robotic System
Deployments
- Customer site
2025-11-12 - XCath announced first-in-human use of its EVR robotic system to treat three patients with complex brain aneurysms at The Panama Clinic. - EVR robotic system / first-in-human procedures - The Panama Clinic
Source
Funding
- 2026-03-12 - Series C - $30M - XCath secures $30M Series C to advance neuro-endovascular surgical robotics
source: businesswire.com
- 2022-01-01 - Series B - $24M - XCath $24M Series B (Crescent Enterprises 2022 report)
source: crescententerprises.com
Investors
- Crescent Enterprises - Lead - Angel / Individual - 2 funding events - repeat backer - first seen 2022-01-01 - latest 2026-03-12
- Dr. Fred Moll - Participant - Unknown - 1 funding event - first seen 2026-03-12
Timeline
Events
- 2026-10-08 - Regulatory - XCath’s Iris surgical robot enters FDA TAP programme
Enrollment follows Iris’s September 2, 2026 Breakthrough Device designation. A dedicated FDA advisor and review-team engagement will cover development decisions, with facilitated input from payers, providers and other stakeholders. Iris remains under development and is not cleared for commercial distribution in any country.
Source - 2026-04-23 - Deployment - XCath Iris completes first in-human telerobotic stroke procedure
Dr. Vitor Mendes Pereira operated from a control room in Santiago, Panama, about 200 kilometres from the patient at Panama Clinic in Panama City. The procedure was overseen locally by principal investigator Dr. Anastasio Ameijeiras Sibauste and used remote robotic mechanical thrombectomy for an ischemic stroke. Crescent Enterprises reported submillimetre precision, no perceptible latency and successful treatment in the landmark remote intervention.
Source - 2026-03-12 - Funding - XCath secures $30M Series C to advance neuro-endovascular surgical robotics
XCath announced a $30M Series C to support development and future commercialization of its endovascular surgical robot. The round was co-led by Crescent Enterprises and Dr. Fred Moll, chairman of XCath's board. The financing brought total capital raised since the company's 2017 founding to $92M.
Source - 2025-11-12 - Deployment - XCath EVR robotic system performs first-in-human brain aneurysm procedures
XCath announced first-in-human use of its EVR robotic system to treat three patients with complex brain aneurysms at The Panama Clinic. The procedures marked only the second time a surgical robot had been used in an intracranial neurovascular intervention. The milestone established a major clinical proof point ahead of commercialization and later Series C financing.
Source - 2022-01-01 - Funding - XCath $24M Series B (Crescent Enterprises 2022 report)
XCath raised additional funding, bringing total capital raised to $24M; Crescent Enterprises cited the round in its 2022 sustainability report. The financing supported advancement of XCath's neuro-endovascular robotic platforms toward regulatory clearances and commercialization. The round is understood to correspond to XCath's earlier Series B.
Source
Relations
Relationships
- The Panama Clinic
Deployment Partner - XCath EVR was used for first-in-human brain aneurysm procedures at The Panama Clinic.